TriCelX, Inc. Announces Opening of Its Flagship Clinic at The Baylor Scott & White Sports Therapy & Research Center at The Star in Frisco, Texas

TriCelX, Inc., (“TriCelX”) a translational leader delivering evidence-based, cost-effective options to alleviate pain as well as to improve aesthetics and physical performance, today announced the opening of its flagship clinic at The Baylor Scott & White Sports Therapy & Research Center at The Star in Frisco, Texas. The clinic was designed and constructed to include an ISO Level 7 (FED 209E class 10,000 classification) cleanroom and is complete with two procedure rooms, each connecting independently to the cleanroom.

Under the company’s LumineX brand, surgeons provide patients with a portfolio of state-of-the-art aesthetic procedures, including futuristic body contouring, non-surgical facial refinement, skin rejuvenation and skin tightening procedures. “I’m excited to have been part of this revolution in aesthetics — moving away from a general surgical world — into a technology-based world, which affords patients with natural options — all without having to go under the knife,” said Dr. Jack Zamora, MD, Chief of Bio-Aesthetics and the creator of the J-Plazty® technique, a minimally-invasive procedure that uses Renuvion® plasma energy sub-dermally to instantly tighten and rejuvenate skin anywhere on the face and body without large incisions, downtime, or the complications of traditional surgery.

Dr. Kristen Aliano Messina, MD Chief of Plastic Surgery & Aesthetics, continued: “Our goal is to transform the field of aesthetics by blending science, technology and art. We aim to translate cutting-edge science and MedTech into evidence-based, personalized solutions to optimize patient outcomes. For example, our XSCULPT™ procedure is a next-generation body sculpting protocol incorporating three state-of-the-art FDA approved technologies:

  • a highly specialized ultrasound technology, which gently breaks down fat cells in the body using ultrasonic sound waves;
  • high-frequency, gentle vibration technology, which uses kinetic energy to further break down and remove the cells with a gentle suction process — allowing undamaged fat cells to be available for fat transfer to other parts of the body;
  • a minimally invasive treatment combining helium gas and radiofrequency energy to create a plasma specially equipped to correct sagging skin and restore a more youthful and natural appearance;
  • the latest in triphasic radiofrequency technology with Attiva for in office procedures.

Under the leadership of double-board-certified Dr. Ryan Hagens, MD, Chief of Musculoskeletal and Regenerative Medicine, OrthodynamiX translates cutting-edge science into evidence-based personalized solutions to help people suffering from pain due to aging, injuries, degenerative and inflammatory conditions. Said Dr. Hagens, “I am most excited to be part of this multi-disciplinary team as we are translating technological advances in aesthetics to provide our patients with individualized treatments options for pain — by leveraging the power of their own unchanged, native adipose cells — all during the same procedure.”

TriCelX’s CEO, Jakes Jordaan, concluded, “With the guidance of our Military Advisory Board, which includes Gen. Lance L. Smith and Brigadier Gen. Mark T. Kimmitt, our team is developing a proprietary biological medical countermeasures cell processing platform — to produce native, non-expanded biologics — to help our warriors facing unique threats such as Acute Radiation Syndrome, Traumatic Brain Injury and battlefield wounds.”

The Baylor Scott & White Sports Therapy & Research Center at The Star – A game-changing sports performance and healthcare destination focused on safety and research in Frisco, Texas at The Star, a sports and entertainment district that is home to the Dallas Cowboys World Headquarters.

SourceTriCelX

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”